Table 1.
Dosage information in FA supplementation and it’s relation with CHD or ASD
| Authors (year) | Intake of folic acid | CHD OR (95% Cl) | ASD OR (95% Cl) |
|---|---|---|---|
| Scanlon KS et al. (1998) [18] | Low-dose group < 245 μg | 1.11 (0.63, 2.00) | |
| Middle-dose group 245–355 μg | 1 | ||
| High-dose group 356–542 μg | 1.30 (0.78, 2.22) | ||
| Shaw GM et al. (2010) [20] | Low-dose group < 293.8 μg | 1.45 (0.87, 2.41) | |
| Middle-dose group 293.8–546.3 μg | 1 | ||
| High-dose group ≥ 546.4 μg | 0.74 (0.41, 1.31) | ||
| Czeizel AE et al. (2015) [25] | Low-dose group 3 mg | 1.06 (0.78, 1.44) | 1.49 (0.65, 3.41) |
| Middle-dose group 6 mg | 1 | 1 | |
| High-dose group 9 mg | 1.14 (0.71, 1.81) | 1.81 (0.51, 6.42) | |
| Mao B et al. (2017) [34] | Low -dose group < 149.88 μg | 1.63 (1.01, 2.62) | 1.44 (0.72, 2.87) |
| Middle-dose group 149.88–266.35 μg | 1 | 1 | |
| High-dose group ≥ 266.35 μg | 1.06 (0.62, 1.81) | 1.07 (0.50, 2.25) |
FA folic acid, CHD congenital heart disease, ASD atrial septal defects